Literature DB >> 8215245

Impairment of retinal increment thresholds in Huntington's disease.

W Paulus1, G Schwarz, A Werner, H Lange, A Bayer, M Hofschuster, N Müller, E Zrenner.   

Abstract

We have investigated detection thresholds for a foveal blue test light using a Maxwellian view system in 61 normal subjects, 19 patients with Huntington's chorea, 14 patients with Tourette's syndrome, and 20 patients with schizophrenia. Ten measurements were made: The blue test light (1 degree diameter, 500 msec duration) was presented either superimposed on a yellow adaptation field (5 degree diameter) or 500 msec after switching off this field (transient tritanopia effect). In both cases five different background intensities were presented. The only abnormality found was in patients with Huntington's chorea. During adaptation these patients' thresholds are significantly higher than normal (p < 0.005). No change was found in the transient tritanopia effect. Huntington's disease causes degeneration of several different transmitter systems in the brain. Increment threshold testing allows for noninvasive investigation of patients and confirms the involvement of the retina in the degenerative process in Huntington's chorea.

Entities:  

Mesh:

Year:  1993        PMID: 8215245     DOI: 10.1002/ana.410340411

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  16 in total

Review 1.  Ophthalmology issues in schizophrenia.

Authors:  Carolina P B Gracitelli; Ricardo Y Abe; Alberto Diniz-Filho; Fabiana Benites Vaz-de-Lima; Augusto Paranhos; Felipe A Medeiros
Journal:  Curr Psychiatry Rep       Date:  2015-05       Impact factor: 5.285

Review 2.  The ubiquitin-proteasome system in retinal health and disease.

Authors:  Laura Campello; Julián Esteve-Rudd; Nicolás Cuenca; José Martín-Nieto
Journal:  Mol Neurobiol       Date:  2013-01-22       Impact factor: 5.590

3.  Optical coherence tomography findings in Huntington's disease: a potential biomarker of disease progression.

Authors:  Hannah M Kersten; Helen V Danesh-Meyer; Dean H Kilfoyle; Richard H Roxburgh
Journal:  J Neurol       Date:  2015-08-02       Impact factor: 4.849

4.  Retinal dysfunction in a presymptomatic patient with Huntington's disease.

Authors:  Jonelle Knapp; Dean A VanNasdale; Keith Ramsey; Julie Racine
Journal:  Doc Ophthalmol       Date:  2018-04-24       Impact factor: 2.379

5.  Retinal Changes in Schizophrenia: A Systematic Review and Meta-analysis Based on Individual Participant Data.

Authors:  Charalampos T Kazakos; Vasilios Karageorgiou
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

Review 6.  Systemic manifestation and contribution of peripheral tissues to Huntington's disease pathogenesis.

Authors:  Chia-Lung Chuang; Fabio Demontis
Journal:  Ageing Res Rev       Date:  2021-05-09       Impact factor: 11.788

Review 7.  Past, present and future role of retinal imaging in neurodegenerative disease.

Authors:  Amir H Kashani; Samuel Asanad; Jane W Chan; Maxwell B Singer; Jiong Zhang; Mona Sharifi; Maziyar M Khansari; Farzan Abdolahi; Yonggang Shi; Alessandro Biffi; Helena Chui; John M Ringman
Journal:  Prog Retin Eye Res       Date:  2021-01-15       Impact factor: 19.704

8.  Color naming deficits and attention-deficit/hyperactivity disorder: a retinal dopaminergic hypothesis.

Authors:  Rosemary Tannock; Tobias Banaschewski; David Gold
Journal:  Behav Brain Funct       Date:  2006-01-27       Impact factor: 3.759

9.  Early retinal function deficit without prominent morphological changes in the R6/2 mouse model of Huntington's disease.

Authors:  Symantas Ragauskas; Henri Leinonen; Jooseppi Puranen; Seppo Rönkkö; Soile Nymark; Kestutis Gurevicius; Arto Lipponen; Outi Kontkanen; Jukka Puoliväli; Heikki Tanila; Giedrius Kalesnykas
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

10.  Effects of estrogen on higher-order cognitive functions in unstressed human females may depend on individual variation in dopamine baseline levels.

Authors:  Lorenza S Colzato; Bernhard Hommel
Journal:  Front Neurosci       Date:  2014-04-07       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.